Laser Treatment of Port Wine Stains
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Medical policy governing coverage of laser treatments for port wine stains for Blue Cross Blue Shield of North Carolina members, including which laser modalities and clinical circumstances are considered medically necessary or investigational.
No material clinical or coverage changes in this revision.
Coverage Criteria
When Pulsed Dye Laser Treatment is covered
Covered when the following location-, age-, and clinical-condition-specific rules are met:
Pulsed dye laser (PDL) covered
Pulsed dye laser (PDL) covered
Pulsed dye laser (PDL) covered
Investigational / Not Covered
The following treatments are considered investigational and are not covered:
BCBSNC does not provide coverage for investigational services or procedures
Cosmetic Exclusion
Not covered when solely cosmetic:
Refer to policy titled 'Cosmetic and Reconstructive Surgery'
BCBSNC considers the following treatments investigational and not covered for port wine stains: Pulsed Dye Laser (PDL) when used in combination with photodynamic therapy or topical angiogenesis inhibitors, and Carbon Dioxide (CO2) lasers. The policy states that BCBSNC does not provide coverage for investigational services or procedures and specifically lists these combinations and modalities as investigational.
This investigational designation is based on the policy’s assessment that there is insufficient evidence that combining topical angiogenesis inhibitors or photodynamic therapy with laser treatment yields superior outcomes compared to laser therapy alone; therefore such combination approaches, as well as CO2 laser use for port wine stains, are excluded from coverage.
Treatment of a port wine stain is not covered when performed solely for cosmetic purposes, including interventions intended only to improve or alter appearance, self-esteem, or to treat psychological or psychosocial complaints related to appearance. Such cosmetic-only indications are excluded from coverage and providers should refer to the BCBSNC policy titled “Cosmetic and Reconstructive Surgery” for further guidance.
When determining medical necessity, documentation should demonstrate clinical indications beyond cosmetic concerns (for example, recurrent bleeding, infection, pain, ulceration, or documented physical functional impairment); absence of such documentation may result in denial.
Coding
| 17106 | Laser destruction of cutaneous vascular proliferative lesion(s) or pigmented lesion (eg, port-wine stain), 1.25 cm or less |
| 17107 | each additional 1.25 cm (List separately in addition to code for primary procedure) |
| 17108 | Laser destruction of cutaneous vascular proliferative lesion(s) or pigmented lesion (eg, port-wine stain), 10.1 sq cm to 20.0 sq cm |
| Q82.5 | Congenital non-neoplastic nevus (port-wine stain) (ICD-10 diagnosis code subject to medical necessity review) |
Provider Actions and Requirements
Prior spot test required
Perform a prior spot test before treatment to select suitable candidates and to assess the degree of scarring that may occur.
- Spot test required to determine candidate suitability
- Spot test required to determine scarring risk
Provide full medical records on request
Be prepared to provide complete medical records when requested; letters of support or explanation alone are not sufficient unless they include all specific information needed to make a medical necessity determination.
- Medical records may be requested for determination of medical necessity
- Letters of support/explanation are useful but insufficient unless complete
Missing documentation may cause denial
BCBSNC may request medical records to determine medical necessity; absence of documentation supporting required clinical indications (for example age or recurrent bleeding/infection/pain/ulceration or documented physical functional impairment) can lead to denial of coverage.
- Lack of documentation supporting clinical indications may trigger denial
Background
Port wine stains are congenital vascular malformations present at birth that typically persist and often become darker and thicker over time. They most commonly involve the face and neck and vary in depth, generally measuring approximately 1 to 5 mm in thickness.
Pulsed Dye Laser (PDL; ~585–600 nm) is the most commonly used laser for these lesions, targeting oxyhemoglobin and deoxyhemoglobin and typically penetrating up to about 2 mm into the skin. Longer-wavelength lasers such as Nd:YAG (1064 nm) and Alexandrite (755 nm) may be used for hypertrophic or resistant lesions but have greater tissue penetration and carry a higher risk of scarring.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.